September 26, 2012

EASD Abstracts Highlight Sanofi Commitment to Advancing Therapeutic Solutions in Diabetes Care

– Findings to be presented from the ORIGIN trial plus clinical data on Lantus® (insulin glargine), Apidra® (insulin glulisine) and Lyxumia® (lixisenatide)*, an investigational GLP-1 receptor agonist –

 

EASD Abstracts Highlight Sanofi Commitment to Advancing Therapeutic Solutions in Diabetes Care
– Findings to be presented from the ORIGIN trial plus clinical data on Lantus® (insulin glargine), Apidra® (insulin glulisine) and Lyxumia® (lixisenatide)*, an investigational GLP-1 receptor agonist –

Paris, France – September 26, 2012 – Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that clinical data supporting its integrated portfolio of therapeutic solutions and demonstrating its ongoing commitment to advancing diabetes care will be presented at the European Association for the Study of Diabetes (EASD) 48th Annual Meeting in Berlin, Germany (October 1-5, 2012).